Amneal Posts 6-Cent Loss Per Share in Third Quarter
AMRX has more than doubled off its 52-week low of $10.06.
Summary
Amneal reported a third-quarter loss of $21.7 million, or 6 cents per share, a negative print for a company that just posted strong Q2 results in August, while revenue came in at $862.7 million and adjusted EPS was 26 cents. The quarter is the first to include the Kashiv BioSciences acquisition closed August 10, so the loss likely reflects integration and deal-related costs layered onto the base business. The stock trades near $20 with a roughly $7 billion market cap, so a loss print against a profitable prior quarter is a meaningful swing in the near-term earnings story. The 8-K/A filed October 23 gave investors Kashiv's audited financials and pro forma results, setting the bar for this first combined quarter.
At the time of this announcement, AMRX was trading at $20.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.1B. The 52-week trading range was $10.06 to $21.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.